Skip to main content
. Author manuscript; available in PMC: 2014 Jul 29.
Published in final edited form as: Stroke. 2011 Jun 2;42(7):1952–1955. doi: 10.1161/STROKEAHA.110.612358

Table 1.

Estimate of Recombinant Tissue-Type Plasminogen Activator Use for Acute Ischemic Stroke (ICD-9 433, 434, 436) From Premier and Medicare Provider and Analysis Review National Databases

FY 2005 FY 2006 FY 2007 FY 2008 FY 2009
MEDPAR
  Total no. of ischemic stroke cases DRG 14/15/524/559 254 530 236 258 223 483 217 798 213 888
  No. with ICD-9 code 99.10 (%) 2908 (1.1) 4793 (2.0) 5320 (2.4) 6013 (2.8) 7201 (3.4)
Premier Database
  Total no. of ischemic stroke cases, DRG 14/15/524/559, age older than 65 y 37 878 41 622 41 730 42 285 44 259
  No. with ICD-9 code 99.10 (%) 459 (1.2) 842 (2.0) 979 (2.3) 1266 (3.0) 1509 (3.4)
  No. with pharmacy billing for thrombolytic (%)* 844 (2.2) 1124 (2.7) 1246 (3.0) 1548 (3.7) 1857 (4.2)
  Total no. of cases, DRG 14/15/524/559, all ages 55 402 61 168 61 560 62 754 66 080
  No. with ICD-9 code 99.10 (%) 774 (1.4) 1417 (2.3) 1628 (2.6) 1944 (3.1) 2418 (3.7)
  No. with pharmacy billing for thrombolytic (%)* 1343 (2.4) 1852 (3.0) 2036 (3.3) 2391 (3.8) 2952 (4.5)

DRG indicates diagnosis-related group; FY, fiscal year; ICD-9, International Classification of Diseases 9th revision; MEDPAR, Medicare Provider and Analysis Review.

*

Including alteplase 100 mg, alteplase 50 mg, alteplase 20 mg, alteplase misc, retavase, tenectaplase, urokinase, excluding streptokinase, and alteplase 1 mg.